News

Aug 22, 2023

ImmunoGen drug prolongs survival in advanced ovarian cancer

By Adam Feuerstein June 4, 2023 CHICAGO — An antibody that delivers chemotherapy

By Adam Feuerstein June 4, 2023

CHICAGO — An antibody that delivers chemotherapy directly to tumor cells extended the lives of women with a form of advanced ovarian cancer in a large study, researchers reported Sunday.

The drug, called Elahere, is made by the biotech company ImmunoGen. It was granted conditional approval in the U.S. last November based on preliminary evidence showing it shrank tumors. The new findings demonstrating prolonged survival will likely lead to a final approval and broader use by physicians who treat women with ovarian cancer, experts said.

advertisement

In the study, participants treated with the drug lived for a median of 16.5 months compared to just under 13 months for participants treated with standard chemotherapy. Statistically, Elahere reduced the risk of death by 33%. The drug also shrank tumors and delayed disease progression.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

Senior Writer, Biotech

Adam Feuerstein is STAT's national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

ASCO23

biotechnology

cancer

This name will appear with your comment

There was an error saving your display name. Please check and try again.